Effect of immortal time bias on the association between immune-related adverse events and oncological outcomes following immune checkpoint inhibitors therapy for head and neck squamous cell carcinoma

Tamura, Koichi; Takenaka, Yukinori; Hosokawa, Kiyohito; Sato, Takashi; Tsuda, Takeshi; Eguchi, Hirotaka; Suzuki, Masami; Fukusumi, Takahito; Suzuki, Motoyuki; Inohara, Hidenori

doi:https://doi.org/10.1371/journal.pone.0314209

Effect of immortal time bias on the association between immune-related adverse events and oncological outcomes following immune checkpoint inhibitors therapy for head and neck squamous cell carcinoma

Tamura, Koichi; Takenaka, Yukinori; Hosokawa, Kiyohito et al.

PLoS ONE, 2024, 19(11), e0314209

アクセス数:1,547件（2025-08-24 04:06 集計）

固定URL: https://hdl.handle.net/11094/99700

閲覧可能ファイル

ファイル	フォーマット	利用条件	サイズ	閲覧回数	利用開始日	説明	information
PLoSONE_19_11_e0314209	pdf	なし	736 KB	31	2025.01.20

Creative Commons : 表示

論文情報

ファイル出力 EndNote Basic出力 Mendeley出力

タイトル	Effect of immortal time bias on the association between immune-related adverse events and oncological outcomes following immune checkpoint inhibitors therapy for head and neck squamous cell carcinoma
著者	著者名 Tamura, Koichi
	NRID 1000040598398 1000040598398 ORCID 0000-0002-3135-5635 0000-0002-3135-5635 researchmap permalink yukinoritakenaka yukinoritakenaka Scopus Author ID 7102054128 7102054128 著者名 Takenaka, Yukinori
	NRID 1000060625896 1000060625896 researchmap permalink drink drink Scopus Author ID 55914870000 55914870000 ORCID 0000-0002-5169-1038 0000-0002-5169-1038 著者名 Hosokawa, Kiyohito
	NRID 1000030756002 1000030756002 researchmap permalink 4501 4501 Scopus Author ID 7406982585 7406982585 著者名 Sato, Takashi
	NRID 1000000778631 1000000778631 researchmap permalink gam92471 gam92471 著者名 Tsuda, Takeshi
	researchmap permalink eguchi-hirotaka eguchi-hirotaka Scopus Author ID 57203344374 57203344374 著者名 Eguchi, Hirotaka
	NRID 1000080434182 1000080434182 researchmap permalink msuzukicgi msuzukicgi Scopus Author ID 57199980789 57199980789 著者名 Suzuki, Masami
	NRID 1000070623734 1000070623734 researchmap permalink 2933 2933 Scopus Author ID 54893429600 54893429600 ORCID 0009-0002-1857-7548 0009-0002-1857-7548 著者名 Fukusumi, Takahito
	NRID 1000050632329 1000050632329 researchmap permalink motoyukisuzuki motoyukisuzuki Scopus Author ID 55505806400 55505806400 著者名 Suzuki, Motoyuki
	NRID 1000000273657 1000000273657 researchmap permalink read0046473 read0046473 Scopus Author ID 7004501837 7004501837 著者名 Inohara, Hidenori
内容	Tamura K et al. (2024) Effect of immortal time bias on the association between immune-related adverse events and oncological outcomes following immune checkpoint inhibitors therapy for head and neck squamous cell carcinoma. PLoS ONE 19(11): e0314209 doi: 10.1371/journal.pone.0314209.
抄録	Immune checkpoint inhibitors (ICIs) are pharmacological agents indicated for recurrent and metastatic head and neck squamous cell carcinoma (HNCSCC). Immune-related adverse events (irAEs) have been reported as predictors of therapeutic response to ICIs. However, previous studies have not adequately addressed the immortal time bias. Therefore, we aimed to investigate the association between the onset of irAEs and oncological outcomes, accounting for immortal time bias. We conducted a retrospective study involving 130 patients with HNSCC who were treated with ICIs. The objective response, progression-free survival (PFS), and overall survival (OS) were assessed using logistic regression analysis, the Kaplan–Meier method, and the Cox proportional hazard (PH) model. The immortal time bias was considered using a landmark analysis and an extended Cox (EC) model. The odds ratios for response and disease control were smaller in the landmark than in the naïve analyses. In the landmark analysis, the 1-year PFS rates were 47.6% and 27.2% for irAE+ and irAE- patients, respectively (p = 0.049), and the 1-year OS rates were 85.7% and 66.5%, respectively (p = 0.006). Regarding PFS, the adjusted HRs for irAEs were 0.49 (95% confidence interval (CI) 0.28–0.85) in the PH analysis and 0.75 (95% CI 0.40–1.40) in the EC analysis. As for OS, the adjusted HRs for irAEs were 0.36 (95% CI 0.19–0.66) in the PH analysis and 0.51 (95% CI 0.27–0.95) in the EC analysis. IrAEs were an independent prognostic factor for OS but not PFS. Without considering the immortal time bias, the association between irAEs and oncologic outcomes in patients with HNSCC treated with ICIs was overestimated. Therefore, the balance between the benefits and risks of ICI therapy must be carefully weighed in clinical settings.
出版者	Public Library of Science
収録物名	PLoS ONE
巻(号)	19(11)
ページ	e0314209
刊行年月	2024-11-25
言語	英語
ハンドルURL	https://hdl.handle.net/11094/99700
eISSN	19326203
関連情報 (isIdenticalTo)	DOI (出版社版) https://doi.org/10.1371/journal.pone.0314209
アクセス権	open access
権利情報	This article is licensed under a Creative Commons Attribution 4.0 International License.
出版タイプ	Version of Record
カテゴリ	学術雑誌論文 Journal Article

資源タイプ	学術雑誌論文
ローカル資源タイプ	学術雑誌論文
DCTERMS.bibliographicCitation	PLoS ONE. 2024, 19(11), p. e0314209
DC.title	Effect of immortal time bias on the association between immune-related adverse events and oncological outcomes following immune checkpoint inhibitors therapy for head and neck squamous cell carcinoma
DC.creator	Tamura, Koichi
	Takenaka, Yukinori
	Hosokawa, Kiyohito
	Sato, Takashi
	Tsuda, Takeshi
	Eguchi, Hirotaka
	Suzuki, Masami
	Fukusumi, Takahito
	Suzuki, Motoyuki
	Inohara, Hidenori
DC.publisher	Public Library of Science
DC.language' scheme='DCTERMS.RFC1766	英語
DCTERMS.issued' scheme='DCTERMS.W3CDTF	2024-11-25
DC.identifier	https://doi.org/10.1371/journal.pone.0314209
DC.description	Tamura K et al. (2024) Effect of immortal time bias on the association between immune-related adverse events and oncological outcomes following immune checkpoint inhibitors therapy for head and neck squamous cell carcinoma. PLoS ONE 19(11): e0314209 doi: 10.1371/journal.pone.0314209.
DCTERMS.abstract	Immune checkpoint inhibitors (ICIs) are pharmacological agents indicated for recurrent and metastatic head and neck squamous cell carcinoma (HNCSCC). Immune-related adverse events (irAEs) have been reported as predictors of therapeutic response to ICIs. However, previous studies have not adequately addressed the immortal time bias. Therefore, we aimed to investigate the association between the onset of irAEs and oncological outcomes, accounting for immortal time bias. We conducted a retrospective study involving 130 patients with HNSCC who were treated with ICIs. The objective response, progression-free survival (PFS), and overall survival (OS) were assessed using logistic regression analysis, the Kaplan–Meier method, and the Cox proportional hazard (PH) model. The immortal time bias was considered using a landmark analysis and an extended Cox (EC) model. The odds ratios for response and disease control were smaller in the landmark than in the naïve analyses. In the landmark analysis, the 1-year PFS rates were 47.6% and 27.2% for irAE+ and irAE- patients, respectively (p = 0.049), and the 1-year OS rates were 85.7% and 66.5%, respectively (p = 0.006). Regarding PFS, the adjusted HRs for irAEs were 0.49 (95% confidence interval (CI) 0.28–0.85) in the PH analysis and 0.75 (95% CI 0.40–1.40) in the EC analysis. As for OS, the adjusted HRs for irAEs were 0.36 (95% CI 0.19–0.66) in the PH analysis and 0.51 (95% CI 0.27–0.95) in the EC analysis. IrAEs were an independent prognostic factor for OS but not PFS. Without considering the immortal time bias, the association between irAEs and oncologic outcomes in patients with HNSCC treated with ICIs was overestimated. Therefore, the balance between the benefits and risks of ICI therapy must be carefully weighed in clinical settings.
DC.rights	This article is licensed under a Creative Commons Attribution 4.0 International License.
DC.format	99700
citation_title	Effect of immortal time bias on the association between immune-related adverse events and oncological outcomes following immune checkpoint inhibitors therapy for head and neck squamous cell carcinoma
citation_author	Tamura, Koichi
	Takenaka, Yukinori
	Hosokawa, Kiyohito
	Sato, Takashi
	Tsuda, Takeshi
	Eguchi, Hirotaka
	Suzuki, Masami
	Fukusumi, Takahito
	Suzuki, Motoyuki
	Inohara, Hidenori
citation_publisher	Public Library of Science
citation_language	英語
citation_date	2024-11-25
citation_journal_title	PLoS ONE
citation_volume	19
citation_issue	11
citation_firstpage	e0314209
citation_doi	https://doi.org/10.1371/journal.pone.0314209
citation_public_url	https://hdl.handle.net/11094/99700

Effect of immortal time bias on the association between immune-related adverse events and oncological outcomes following immune checkpoint inhibitors therapy for head and neck squamous cell carcinoma

閲覧可能ファイル

論文情報

論文詳細を表示